AmoyDx® HRD Complete Panel
Machine-learning assessment of genome-wide copy-number patterns for confident HRD characterization.
Longer PFS with PARPi Treatment for GSS-positive Group
The study highlights the promising value of GSS in identifying patients who may respond favorably to PARPi treatment.
White Paper
1. Comparative Analysis of HRD Complete Data on MGI DNBSEQ-G50 and NextSeq 550
The study confirms that the AmoyDx® HRD Complete Panel performs exceptionally well on both MGI G50 and NextSeq 550 platforms. The MGI G50 demonstrated superior sequencing quality and data QC performance while maintaining comparable accuracy in SNVs/InDels and HDs detection as well as HRD (GSS) assessment. These findings validate MGI G50 as a robust and reliable platform for HRR gene mutation screening and HRD (GSS) status analysis.Mutations( Hover over each mutational type to highlight genes covered )
ATM
BARD1
BRCA1
BRCA2
BRIP1
CDH1
CDK12
CHEK1
CHEK2
FANCA
FANCL
HDAC2
PALB2
PPP2R2A
PTEN
RAD51B
RAD51C
RAD51D
RAD54L
TP53
Fast turnaroud time within
3 days
Cost- effective
Streamlined one-tube workflow
Secure data analysis and interpretation
Specifications
Publications
1. Feng, Cong et al. Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score. The Breast, Volume 69, 392 - 400.
2. Yuan W, Ni J, Wen H, Shi W, Chen X, Huang H, et al. Genomic Scar Score: A robust model predicting homologous recombination deficiency based on genomic instability. BJOG. 2022; 129(Suppl. 2): 14–22.